表皮生长因子受体拮抗剂在肿瘤靶向治疗中的应用  

Progress in application of epidermal growth factor receptor inhibitors in cancer target therapy

作　　者：杜亚利[1] 李琼 

机构地区：[1]兰州军区总医院安宁分院老年病科,甘肃兰州730070 [2]兰州市第四医院检验科,甘肃兰州730050

出　　处：《兰州大学学报（医学版）》2009年第3期99-102,108,共5页Journal of Lanzhou University（Medical Sciences）

摘　　要：大多数人类上皮细胞癌是以生长因子及表皮生长因子受体(EGFR)家族的功能性活化为标志的。EGFR是最先被提出作为癌症治疗靶点的生长因子受体,现已有4种EGFR拮抗剂在临床上用于治疗非小细胞肺癌、头颈部鳞状细胞癌、结肠癌和胰腺癌等实体肿瘤。概述了EGFR拮抗剂的结构、生理功能、作用机制及其临床抗癌活性,以及未来研究方向。The majority of human epithelial cancers are marked by functional activation of growth factors and the epidermal growth factor receptor （EGFR） family. EGFR was the first growth factor receptor to be proposed as a target for cancer therapy. Four EGFR antagonists are currently available for the treatment in clinic non-small-cell lung cancer, squamous-cell carcinoma of the head and neck, colorectal cancer, pancreatic cancer and other solid tumors. The structure, physiological function, mechanisms of action, and anticancer activity of the EGFR inhibitors was reviewed, and considers the future directions of study.

关 键 词：表皮生长因子受体 酪氨酸激酶抑制剂 单克隆抗体 靶向治疗 肿瘤 

分 类 号：R730.53[医药卫生—肿瘤]